At an MDA-sponsored symposium, stakeholders interested in drug development for rare diseases met to discuss moving experimental therapies from lab to clinic
Enhancing collaboration and transfer of technology between academia and industry was the subject of MDA's recent Translational Research Symposium, one of a series of four MDA-sponsored research symposia scheduled in 2012.
The symposium was held June 27 in New Orleans, in conjunction with the 2012 New Directions in Biology and Disease of Skeletal Muscle Conference.
About 150 people attended and heard speakers drawn from the biotechnology and pharmaceutical industries, academia, voluntary health organizations and the U.S. National Institutes of Health.
Jane Larkindale, MDA's director of translational research, was among the presenters.
Attendees learned that, to enhance the chances of partnering with the pharmaceutical industry, investigators conducting early-stage research should:
"Translating research from a laboratory setting to an effective therapeutic agent is a very difficult process," Larkindale said. "During this symposium, the various stakeholders in the process learned more about how the other groups operate and how to work together more efficiently. There is real interest from large companies to develop therapies for rare diseases at this time, and MDA aims to help get new ideas from our basic science program into truly translational studies."
To learn more about translational research and MDA's role in funding it, see the following:
In addition to the translational research symposium, MDA’s 2012 series includes three other meetings: